Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1995-04-21
1997-09-23
Webman, Edward J.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424494, 424497, 424498, 424499, 514781, A61K 916, A61K 4738
Patent
active
056701721
ABSTRACT:
A controlled release composition including spheroid cores of diltiazem or a pharmaceutically acceptable salt thereof and optionally a spheronizing agent, the cores being coated with a controlled release layer, and a method of manufacturing the same, is disclosed. The spheronizing agent when present is preferably microcrystalline cellulose. Ethylcellulose is a preferred release coating. The controlled release coating preferably contains a plasticizer, a surfactant and a tack-modifier.
REFERENCES:
patent: 4456628 (1984-06-01), Bauer et al.
patent: 4721619 (1988-01-01), Panoz et al.
patent: 4808413 (1989-02-01), Joshi et al.
patent: 4894240 (1990-01-01), Geoghegan et al.
patent: 4917899 (1990-04-01), Geoghegan et al.
patent: 4917900 (1990-04-01), Junes et al.
patent: 4960596 (1990-10-01), Debregeas et al.
patent: 5002776 (1991-03-01), Geoghegan et al.
patent: 5112621 (1992-05-01), Stevens et al.
patent: 5219621 (1993-06-01), Geoghegan et al.
patent: 5286497 (1994-02-01), Hendrickson et al.
patent: 5364620 (1994-11-01), Geoghegan et al.
(Abstract), Pharmaceuticals, p. 8, Week K23, Abstract #54403 K/23 (EP-80-341), "Pharmaceutical multiple units formulation -with enterically coated cores for reduced peak plasma drug concentration", Benzon A AS.
(Abstract) Pharmaceuticals, Week K25, Abstract #59112 K/25 (EP-81-006), "Composition of beta-adrenergic blocer and tetra-hydro-benzazepine -useful as atihypertensive and in improving efficiency of kidney function", Alcide Co. Ltd. Partn (ALLI).
(Abstract) Pharmaceuticals, p. 3, Week 8407, Abstract #84-038350/07 (EP-100-061-A), "Pharmaceutical dosage units with enhanced bio:availability -especially hydro:chloro:thiazide-triameterene mixtures for uniform absoprtion", Mylan Pharm, Inc.
(Abstract) Pharmaceuticals, p. 6, Week 8528, Abstract #85-166500/28 (EP-147-780-A), "Pharmaceutical composition for oral, rectal or vaginal administration -with polvinyl alcohol film coating for controlled and prolonged release", (Merck & Co., Inc.
(Abstract) No. 22342C/13 (EP-9-657), "Diuretic compositions containing potassium retaining agents -comprising 2,4-di:amino-5-aminobenzl-pyrimidine derivatives", Hoffman-LaRoche AG.
(Abstract) No. 1593062, "Pharmaceutical controlled release compositions", 16 Sep. 1977, Richter Gedeon Vegyeszeti Gyar RT.
(Abstract), No. 85-184021/31 (EP-154-009-A), "Treatment of hypertension in patent -by administration of thiazide diuretic at level to cause antihypetensive action with diuresia", Euro-Celtique, S.A.
(Abstract), No. 89-158961/22 (EP-317-855-A), "Combination of moxonidine, hydro:chloro:thiazide and opt. triamteren -for long-term treatment of hypertonia and oedemas", Beiersdorf AG.
Buxton Ian Richard
Critchley Helen
Leslie Stewart Thomas
Malkowska Sandra Therese Antoinette
Miller Ronald Brown
Euro-Celtique S.A.
Webman Edward J.
LandOfFree
Pharmaceutical spheroid formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical spheroid formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical spheroid formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1937878